Drugs / AKS-452X
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05124483 | Apr → Jul 2022 | COVID-19 | University Medical Center Groningen | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AKS-452X | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05124483 ↗ |
| Modality | Vaccine | “SP/RBD-Fc antigen booster vaccine (AKS-452X)” NCT05124483 ↗ |
| Route | Subcutaneous | “administered via s.c. route” NCT05124483 ↗ |